Prime Highlight:
- Burjeel Cancer Institute (BCI) signed an MoU with Avesta Bio to accelerate AI-powered cancer research and expand access to advanced treatments in the UAE and region.
- The collaboration aims to enhance precision medicine, improve patient outcomes, and strengthen Abu Dhabi’s position as a global hub for medical innovation.
Key Facts:
- The partnership includes plans for joint clinical research, multi-phase trials, and knowledge sharing to meet international oncology standards.
- The initiative aligns with the UAE’s national strategy to build a world-class, AI-driven healthcare system and foster regional leadership in scientific research.
Background
Burjeel Cancer Institute (BCI), part of Burjeel Holdings, has signed a Memorandum of Understanding (MoU) with Avesta Bio, a US biotechnology company that develops AI-based cancer treatments. The partnership will speed up cancer research and make advanced treatments more available in the UAE and the region.
Under the agreement, both organisations will explore joint clinical research opportunities, including multi-phase clinical trials for Avesta Bio’s novel cancer therapies. The collaboration will also strengthen research infrastructure, encourage knowledge sharing, and promote the development of advanced treatments that meet global oncology standards.
“Real breakthroughs in cancer care occur when medical expertise is combined with technology-powered intelligence,” said Prof. Humaid Al Shamsi, CEO of BCI. “Through this partnership, we can enhance treatment precision and improve patients’ quality of life.”
Prof. Khaled Musallam, Chief Research Officer at Burjeel Holdings, said the collaboration supports the UAE’s vision to build a strong research ecosystem. “Participating in early-stage drug development helps transform the region from being a consumer of innovation into a creator of it,” he added.
Avesta Bio leaders said the UAE offers an ideal environment for pioneering cancer research. “The UAE’s focus on science, technology, and human talent aligns perfectly with our mission of delivering ‘Hope Without Harm,’” said Ian Akash Morrison, CEO and Co-Founder of Avesta Bio.
The partnership supports the UAE’s national strategy to build a world-class healthcare system powered by artificial intelligence and global collaboration, reinforcing Abu Dhabi’s growing role as a center for medical innovation and advanced research.
